Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 2Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 31Rituximab 22Vincristine 19Doxorubicin 17Filgrastim 15Prednisone 14Peripheral Blood Stem Cell Transplantation 14Etoposide 13Cytarabine 12Magnetic Resonance Spectroscopy 10fludarabine phosphate 9Radiotherapy 9Bortezomib 9Biopsy 9Cyclosporine 8Specimen Handling 7Methotrexate 7Dexamethasone 7X-Rays 6Vorinostat 6Phantoms, Imaging 6Leucovorin 6Lenalidomide 6tanespimycin 5sargramostim 5fludarabine 5bryostatin 1 5aldesleukin 5Nuclear Medicine Department, Hospital 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Non-Hodgkin × Pentetic Acid × Clear all
NCT00001575 2015-12-07

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
87 enrolled 11 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡